Gilead Sciences Partners with Merus for Groundbreaking Antibody-Based Research
Wednesday, 6 March 2024, 15:01
Gilead Sciences to Invest in Merus
Gilead Sciences (GILD) has announced a groundbreaking partnership with Merus (MRUS) through a $25 million investment for research collaboration.
Research Deal for Trispecific T-Cell Engagers
- Gilead Sciences (GILD) to collaborate with Merus (MRUS) on developing antibody-based trispecific T-cell engagers, aiming to revolutionize biopharmaceutical treatments.
This strategic investment highlights a significant milestone in advancing cutting-edge therapies in the biopharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.